EVM
EGRX

Eaton Vance Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Eaton Vance Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-236
Closed -$12K – 2800
2021
Q4 		$12K Buy
236
+11
+5% +$570 ﹤0.01% 2512
2021
Q3 		$4K Buy
225
+164
+269% +$8.07K ﹤0.01% 1858
2021
Q2 		$3K Buy
61
+9
+17% +$371 ﹤0.01% 2696
2021
Q1 		$2K Buy
+52
New +$2.41K ﹤0.01% 2799

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SGCIA
Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Eaton Vance Management's EGRX Position: Q1 2022 in Review

Eaton Vance Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2022, closing a stake of 236 shares — an estimated $12K sold.

Eaton Vance Management first reported a position in EGRX in Q1 2021 and held it in 4 quarters. The position peaked at $12K in Q4 2021. 160 funds tracked by Wall St. Rank hold EGRX as of Q1 2022.

  • Eaton Vance Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
  • Eaton Vance Management sold 236 Eagle Pharmaceuticals, Inc. shares in Q1 2022, an estimated $12K.
  • Eaton Vance Management first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2021 and held it in 4 quarters.
  • Eaton Vance Management's Eagle Pharmaceuticals, Inc. position peaked at $12K in Q4 2021.
  • 160 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.